Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Selvarangan R, Wu WK, Nguyen TT, Carlson L, Wallis CK, Stiglich SK, Chen YC, Jost KC Jr, Prentice JL, Wallace RJ Jr, Barrett SL, Cookson BT, Coyle MB, 2004. Characterization of a novel group of mycobacteria and proposal of Mycobacterium sherrisii sp. nov. J Clin Microbiol 42: 52–59.
-
2.
van Ingen J, Tortoli E, Selvarangan R, Coyle MB, Crump JA, Morrissey AB, Dekhuijzen PN, Boeree MJ, van Soolingen D, 2011. Mycobacterium sherrisii sp. nov., a slow-growing non-chromogenic species. Int J Syst Evol Microbiol 61: 1293–1298.
-
3.
Gamperli A, Bosshard PP, Sigrist T, Brandli O, Wildermuth S, Weber R, Mueller NJ, 2005. Pulmonary Mycobacterium sherrisii infection in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol 43: 4283–4285.
-
4.
Loulergue P, Lamontagne F, Vincent V, Rossier A, Pialoux G, 2007. Mycobacterium sherrisii: a new opportunistic agent in HIV infection? AIDS 21: 893–894.
-
5.
Tortoli E, Galli L, Andebirhan T, Baruzzo S, Chiappini E, de Martino M, Brown-Elliott BA, 2007. The first case of Mycobacterium sherrisii disseminated infection in a child with AIDS. AIDS 21: 1496–1498.
-
6.
Tortoli E, Mariottin A, Mazzarelli G, 2007. Mycobacterium sherrisii isolation from a patient with pulmonary disease. Diagn Microbiol Infect Dis 57: 221–223.
-
7.
Barrera L, Palmero D, Paul R, Lopez B; Grupo de Investigacion de M. simiae, 2010. Disease due to Mycobacterium simiae and “Mycobacterium sherrisii” in Argentina. Medicina (B Aires) 70: 343–346.
-
8.
Ho J, Balm M, Huggan P, Chew N, Venkatachalam I, Archuleta S, 2012. Immune reconstitution inflammatory syndrome associated with disseminated Mycobacterium sherrisii infection. Int J STD AIDS 23: 369–370.
-
9.
Crump JA, van Ingen J, Morrissey AB, Boeree MJ, Mavura DR, Swai B, Thielman NM, Bartlett JA, Grossman H, Maro VP, van Soolingen D, 2009. Invasive disease caused by nontuberculous mycobacteria, Tanzania. Emerg Infect Dis 15: 53–55.
-
10.
Valero G, Moreno F, Graybill J, 1994. Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in a murine model of disseminated infection. Antimicrob Agents Chemother 38: 2676–2677.
-
11.
van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL, 2012. In vitro synergy between clofazimine and amikacin in nontuberculous mycobacterial disease. Antimicrob Agents Chemother 56: 5324–6327.
-
12.
van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL, 2012. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 39: 173–176.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 26 | 26 | 7 |
| Full Text Views | 446 | 215 | 0 |
| PDF Downloads | 55 | 11 | 0 |
Disseminated Infection by Mycobacterium sherrisii and Histoplasma capsulatum in an African HIV-Infected Patient
Juan Taján
Juan Taján
Hospital de Sabadell and UDIAT Diagnostic Centre, Corporació Sanitària Parc Taulí, Sabadell; Department of Infectious Diseases and Microbiology Laboratory, Universitat Autònoma de Barcelona, Barcelona, Spain; Campus d´Excellència Internacional, Bellaterra, Spain; Microbiology Department-CDB, Hospital Clínic de Barcelona-Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain; Pathology, Pharmacology and Microbiology Departments, University of Barcelona (UB), Barcelona, Spain
Search for other papers by Juan Taján in
Current site
Google Scholar
PubMed
Search for other papers by Juan Taján in
Current site
Google Scholar
PubMed
Mateu Espasa
Mateu Espasa
Hospital de Sabadell and UDIAT Diagnostic Centre, Corporació Sanitària Parc Taulí, Sabadell; Department of Infectious Diseases and Microbiology Laboratory, Universitat Autònoma de Barcelona, Barcelona, Spain; Campus d´Excellència Internacional, Bellaterra, Spain; Microbiology Department-CDB, Hospital Clínic de Barcelona-Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain; Pathology, Pharmacology and Microbiology Departments, University of Barcelona (UB), Barcelona, Spain
Search for other papers by Mateu Espasa in
Current site
Google Scholar
PubMed
Search for other papers by Mateu Espasa in
Current site
Google Scholar
PubMed
Montserrat Sala
Montserrat Sala
Hospital de Sabadell and UDIAT Diagnostic Centre, Corporació Sanitària Parc Taulí, Sabadell; Department of Infectious Diseases and Microbiology Laboratory, Universitat Autònoma de Barcelona, Barcelona, Spain; Campus d´Excellència Internacional, Bellaterra, Spain; Microbiology Department-CDB, Hospital Clínic de Barcelona-Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain; Pathology, Pharmacology and Microbiology Departments, University of Barcelona (UB), Barcelona, Spain
Search for other papers by Montserrat Sala in
Current site
Google Scholar
PubMed
Search for other papers by Montserrat Sala in
Current site
Google Scholar
PubMed
Marta Navarro
Marta Navarro
Hospital de Sabadell and UDIAT Diagnostic Centre, Corporació Sanitària Parc Taulí, Sabadell; Department of Infectious Diseases and Microbiology Laboratory, Universitat Autònoma de Barcelona, Barcelona, Spain; Campus d´Excellència Internacional, Bellaterra, Spain; Microbiology Department-CDB, Hospital Clínic de Barcelona-Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain; Pathology, Pharmacology and Microbiology Departments, University of Barcelona (UB), Barcelona, Spain
Search for other papers by Marta Navarro in
Current site
Google Scholar
PubMed
Search for other papers by Marta Navarro in
Current site
Google Scholar
PubMed
Bernat Font
Bernat Font
Hospital de Sabadell and UDIAT Diagnostic Centre, Corporació Sanitària Parc Taulí, Sabadell; Department of Infectious Diseases and Microbiology Laboratory, Universitat Autònoma de Barcelona, Barcelona, Spain; Campus d´Excellència Internacional, Bellaterra, Spain; Microbiology Department-CDB, Hospital Clínic de Barcelona-Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain; Pathology, Pharmacology and Microbiology Departments, University of Barcelona (UB), Barcelona, Spain
Search for other papers by Bernat Font in
Current site
Google Scholar
PubMed
Search for other papers by Bernat Font in
Current site
Google Scholar
PubMed
Julián González-Martín
Julián González-Martín
Hospital de Sabadell and UDIAT Diagnostic Centre, Corporació Sanitària Parc Taulí, Sabadell; Department of Infectious Diseases and Microbiology Laboratory, Universitat Autònoma de Barcelona, Barcelona, Spain; Campus d´Excellència Internacional, Bellaterra, Spain; Microbiology Department-CDB, Hospital Clínic de Barcelona-Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain; Pathology, Pharmacology and Microbiology Departments, University of Barcelona (UB), Barcelona, Spain
Search for other papers by Julián González-Martín in
Current site
Google Scholar
PubMed
Search for other papers by Julián González-Martín in
Current site
Google Scholar
PubMed
Ferran Segura
Ferran Segura
Hospital de Sabadell and UDIAT Diagnostic Centre, Corporació Sanitària Parc Taulí, Sabadell; Department of Infectious Diseases and Microbiology Laboratory, Universitat Autònoma de Barcelona, Barcelona, Spain; Campus d´Excellència Internacional, Bellaterra, Spain; Microbiology Department-CDB, Hospital Clínic de Barcelona-Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain; Pathology, Pharmacology and Microbiology Departments, University of Barcelona (UB), Barcelona, Spain
Search for other papers by Ferran Segura in
Current site
Google Scholar
PubMed
Search for other papers by Ferran Segura in
Current site
Google Scholar
PubMed
Mycobacterium sherrisii is a new species of opportunistic, slow-growing, non-tuberculous Mycobacterium closely related to Mycobacterium simiae that can currently be identified with the sequence of 16S rARN gene and the heat-shock protein 65. Few cases of patients infected by this Mycobacterium have been reported and all of them were associated with human immunodeficiency virus or other immunosuppressive conditions. Clinical management is complex, because there is not a clear correlation between the in vitro antibiotic susceptibility testing and the patient's clinical outcome.
Author Notes
Authors' addresses: Juan Taján, Corporació Sanitària Parc Taulí, Infectious Diseases, Sabadell, Barcelona, Spain, E-mail: jtajan@tauli.cat. Mateu Espasa, Corporacio Sanitaria Parc Tauli – Microbiology, UDIAT-CD, Sabadell, Barcelona, Spain, E-mail: mespasa@tauli.cat. Montserrat Sala, Marta Navarro, Bernat Font, and Ferran Segura, Corporació Sanitària Parc Taulí - Infectious Diseases, Sabadell, Barcelona, Spain, E-mails: msala@tauli.cat, mnavarro@tauli.cat, bfont@tauli.cat, and fsegura@tauli.cat. Julián González-Martín, Hospital Clínic de Barcelona- Barcelona Centre for International Health Research (CRESIB) - Anatomia Patològica, Pathology, Pharmacology and Microbiology, Barcelona, Barcelona, Spain, E-mail: gonzalez@clinic.ub.es.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Selvarangan R, Wu WK, Nguyen TT, Carlson L, Wallis CK, Stiglich SK, Chen YC, Jost KC Jr, Prentice JL, Wallace RJ Jr, Barrett SL, Cookson BT, Coyle MB, 2004. Characterization of a novel group of mycobacteria and proposal of Mycobacterium sherrisii sp. nov. J Clin Microbiol 42: 52–59.
-
2.
van Ingen J, Tortoli E, Selvarangan R, Coyle MB, Crump JA, Morrissey AB, Dekhuijzen PN, Boeree MJ, van Soolingen D, 2011. Mycobacterium sherrisii sp. nov., a slow-growing non-chromogenic species. Int J Syst Evol Microbiol 61: 1293–1298.
-
3.
Gamperli A, Bosshard PP, Sigrist T, Brandli O, Wildermuth S, Weber R, Mueller NJ, 2005. Pulmonary Mycobacterium sherrisii infection in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol 43: 4283–4285.
-
4.
Loulergue P, Lamontagne F, Vincent V, Rossier A, Pialoux G, 2007. Mycobacterium sherrisii: a new opportunistic agent in HIV infection? AIDS 21: 893–894.
-
5.
Tortoli E, Galli L, Andebirhan T, Baruzzo S, Chiappini E, de Martino M, Brown-Elliott BA, 2007. The first case of Mycobacterium sherrisii disseminated infection in a child with AIDS. AIDS 21: 1496–1498.
-
6.
Tortoli E, Mariottin A, Mazzarelli G, 2007. Mycobacterium sherrisii isolation from a patient with pulmonary disease. Diagn Microbiol Infect Dis 57: 221–223.
-
7.
Barrera L, Palmero D, Paul R, Lopez B; Grupo de Investigacion de M. simiae, 2010. Disease due to Mycobacterium simiae and “Mycobacterium sherrisii” in Argentina. Medicina (B Aires) 70: 343–346.
-
8.
Ho J, Balm M, Huggan P, Chew N, Venkatachalam I, Archuleta S, 2012. Immune reconstitution inflammatory syndrome associated with disseminated Mycobacterium sherrisii infection. Int J STD AIDS 23: 369–370.
-
9.
Crump JA, van Ingen J, Morrissey AB, Boeree MJ, Mavura DR, Swai B, Thielman NM, Bartlett JA, Grossman H, Maro VP, van Soolingen D, 2009. Invasive disease caused by nontuberculous mycobacteria, Tanzania. Emerg Infect Dis 15: 53–55.
-
10.
Valero G, Moreno F, Graybill J, 1994. Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in a murine model of disseminated infection. Antimicrob Agents Chemother 38: 2676–2677.
-
11.
van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL, 2012. In vitro synergy between clofazimine and amikacin in nontuberculous mycobacterial disease. Antimicrob Agents Chemother 56: 5324–6327.
-
12.
van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL, 2012. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 39: 173–176.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 26 | 26 | 7 |
| Full Text Views | 446 | 215 | 0 |
| PDF Downloads | 55 | 11 | 0 |